NEURACAP
Sector OutlookPublished · 22 pages · Free to read

Personal Care Products Sector Outlook — September 2026

A sector view of Personal Care Products across three pricing groups — brand portfolios, private-label suppliers and nutrition sellers — built on forward EV/EBITDA multiples and recorded precedent transactions. For owners, boards and acquirers assessing where a business sits in the range.

For information only. Not an appraisal or a fairness opinion.

What moved since: Personal Care Products M&A update, 14–28 September 2026

Key figures

Top of range
14.2x
EV/EBITDA, CY2027E
Sector median
9.8x
12 of 15 companies rated
Bottom of range
4.0x
EV/EBITDA, CY2027E
Highest disclosed deal multiple
16.2x
LTM EBITDA at announcement

Read the report

NeuraCap

CONSUMER STAPLES › HOUSEHOLD AND PERSONAL PRODUCTS › PERSONAL CARE PRODUCTS

Personal Care Products: One Sector Trading at Two Very Different Valuations

Where value sits across the fifteen companies in this peer set, and what the recorded transactions say buyers agreed to pay for whole companies.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E)

Personal Care Products Coverage | September 2026 | Confidential | Not investment advice

1

1 / 22

Executive summary

Across fifteen public comparables, forward EV/EBITDA for CY2027E ranges from 14.2x at the top to 4.0x at the bottom, with a sector median of 9.8x. Shelf-facing brand portfolios sit near the top of the range, private-label suppliers price inside the middle band, and nutrition sellers sit at the bottom. Recorded transactions echo the same split: a claims-led brand changed hands near 16.2x forward EBITDA, while a cost-led portfolio was agreed near 7.8x. The report sets out where each business type sits and what the recorded evidence is associated with.

Key findings

  • Personal Care Products spans three pricing tiers, 14.2x to 4.0x on forward EBITDA.
  • Nutrition sellers sit at the bottom tier, priced on distributor-driven revenue.
  • Private-label suppliers price inside the middle band, not the bottom.
  • Recent deals price claims-led brands near 16.2x, cost-led ones near 7.8x.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    CONSUMER STAPLES › HOUSEHOLD AND PERSONAL PRODUCTS › PERSONAL CARE PRODUCTS

    This is the cover page identifying the report as a Personal Care Products sector outlook dated September 28, 2026.

    We're opening our Personal Care Products sector outlook, built on market data as of September 28, 2026. What follows sets out where value sits across the peer set and what recorded transactions say buyers have paid for whole companies.

    Everything on this page

    CONSUMER STAPLES › HOUSEHOLD AND PERSONAL PRODUCTS › PERSONAL CARE PRODUCTS Personal Care Products: One Sector Trading at Two Very Different Valuations Where value sits across the fifteen companies in this peer set, and what the recorded transactions say buyers agreed to pay for whole companies. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This page lists the five numbered sections and the appendix that make up the report.

    The report runs five sections plus an appendix, starting with the bottom line so the core finding lands immediately. Even a reader who stops after section one leaves with the full story.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line One Label, Three Different Businesses — and Three Different Prices 02 The Landscape Five Groups Share the Shelf and Sell to Different Buyer Groups 03 Valuation & Situations Ranked on Forward Earnings, the Set Splits into Two Ratings 04 Precedent Transactions Strategics Have Been Paying Mid-Teens; A Sponsor Paid for Cash Earnings 05 Strategic Implications The Moves That Change Where a Business Sits in This Range 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Personal Care Products Trades as Three Markets: Brand Portfolios, Private-Label Self-Care and Nutrition Sellers

    This page states the report's central finding: the sector splits into three distinct pricing groups on forward EV/EBITDA.

    We see the sector split into three markets on EV/EBITDA for CY2027E: the top of the range trades at 14.2x, the bottom at 4.0x, and the sector median sits at 9.8x. Twelve of the fifteen companies on the page carry a forward estimate, so that spread is read on those twelve names. Shelf-facing brand portfolios sit near the top, private-label self-care names sit inside the middle band, and nutrition sellers sit at the bottom. That's the frame we build on through the rest of the deck.

    Everything on this page

    01 · THE BOTTOM LINE Personal Care Products Trades as Three Markets: Brand Portfolios, Private-Label Self-Care and Nutrition Sellers The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (12 of 15 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Two Ends of This Sector Are Priced Like Different Industries On forward EV / EBITDA for CY2027E, the top of the range is carried at 14.2x and the bottom at 4.0x, with the middle of the range at 9.8x. 12 of the 15 companies on the page carry a forward estimate, so the spread is read on those 12 names. 2 Shelf-Facing Portfolios Hold the Top of the Range; Nutrition Sellers Hold the Bottom Mass-market personal care portfolios are 6 of the 15 companies here, and the 4 of them with a forward estimate are carried at 14.1x. The three nutrition and meal-replacement sellers — Herbalife Nutrition Ltd. (HLF), Nature's Sunshine Products, Inc. (NATR) and LifeVantage Corporation (LFVN) — all sit in the bottom tier, where revenue turns on distributor recruitment and retention. 3 Supplying the Price Gap Is Priced Inside the Middle Band, Not at the Bottom The two store-brand and private-label self-care names sit inside the middle band: Haleon plc (HLN) at 11.6x with a 27% margin, alongside Perrigo Company plc (PRGO) at 7.4x with revenue flat at 0%. Where own-label supply and category breadth are the business, the market has been paying inside the middle of the range rather than at the bottom of it. 4 The Higher Announced Multiples Sit with Claims and Distribution, the Lower Ones with Cost-Led Brands Henkel US Operations Corp completed Olaplex Holdings, Inc. in March 2026 at 16.2x forward EBITDA, a claims-led brand landing inside a global distribution network. Two months later, Oaktree Capital Management L.P. announced Spectrum Brands Holdings, Inc. at 7.8x, a cash-generative, cost-led portfolio agreed toward the bottom of the range. 9.8x Sector median EV/EBITDA CY2027E consensus · 12 rated of 15 companies 14.2x Premium end EV/EBITDA vs 4.0x at the discount end top quartile (n=3) against bottom quartile (n=3) on EV/EBITDA — the spread the report explains 25 Transactions with disclosed terms 46 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    This divider introduces the market-map section covering the five groups that share the sector label.

    Next, we map the five groups sharing this sector label and show how each is priced. This sets up the segment view that follows.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Five Groups Share the Shelf and Sell to Different Buyer Groups Who sits in each group, and what its rating is argued on. 02 of 06 Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Five Groups Share One Label, and Buyers Price Them Separately

    This page groups the fifteen approved companies into five segments and shows each segment's median EV/EBITDA.

    We group the fifteen companies in this set into five segments and price each one on its own median EV/EBITDA for CY2027E. Splitting the label this way is what lets us compare like with like instead of averaging distinct businesses together. That segmentation is the foundation for every valuation read that follows.

    Everything on this page

    02 · MARKET MAP Five Groups Share One Label, and Buyers Price Them Separately 15 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 MASS-MARKET PERSONAL CARE PORTFOLIOS 6 cos median 14.1x CL KMB EPC HNST WALD NUS The scale end of the sector: 6 of the 15 companies, holding the shelf mandate and the advertising budgets that come with it. ADJACENT: NUTRITION AND MEAL-REPLACEMENT PRODUCTS 3 cos median 4.0x HLF NATR LFVN Three direct-selling names whose revenue rests on distributor recruitment and retention rather than on retail facings. ADJACENT: PRESCRIPTION DERMATOLOGY THERAPEUTICS 2 cos 11.2x · 1 rated NAGE EVMN Two names selling on claims substantiation and prescriber trust, of which one carries a forward estimate. STORE-BRAND AND PRIVATE-LABEL SELF-CARE 2 cos median 9.5x HLN PRGO Two suppliers sitting on the other side of the price gap, earning on manufacturing scale and retailer mandates. ADJACENT MODELS 2 cos median 8.1x BLCO PBH Bausch + Lomb Corporation (BLCO) and Prestige Consumer Healthcare Inc. (PBH): consumables and over-the-counter remedies bought on replenishment cadence.

  6. 06
    02 · LANDSCAPE

    Brand Portfolios Carry the Scale; Nutrition Sellers Carry the Discount

    This page compares the scale of brand portfolios against the discount carried by nutrition sellers.

    Brand portfolios carry the scale in this set, while nutrition sellers carry the discount — at the top, the rated portfolios sit near 14.1x, and at the bottom, the nutrition names sit near 4.0x. That gap tells us the market is pricing distribution power and claim strength differently from distributor-driven revenue. Full company detail sits in the appendix for anyone who wants to check a specific name.

    Everything on this page

    02 · LANDSCAPE Brand Portfolios Carry the Scale; Nutrition Sellers Carry the Discount Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Mass-market personal care portfolios 6 40% 14.1x Colgate-Palmolive Company (CL) · Kimberly-Clark Corporation (KMB) · +4 more Shelf mandate and scale. 6 of the 15 companies, and the 4 with forward estimates are carried at 14.1x — Colgate-Palmolive Company (CL) and Kimberly-Clark Corporation (KMB) at one end of size, The Honest Company, Inc. (HNST) and Waldencast plc (WALD) at the other. The debate on these names runs on price/mix and advertising weight rather than on volume. Adjacent: nutrition and meal-replacement products 3 20% 4.0x Herbalife Nutrition Ltd. (HLF) · Nature's Sunshine Products, Inc. (NATR) · +1 more Direct selling, distributor churn. Herbalife Nutrition Ltd. (HLF), Nature's Sunshine Products, Inc. (NATR) and LifeVantage Corporation (LFVN) all carry estimates, spanning 2.9x to 6.6x on forward EBITDA. Recruitment-led revenue and compensation-plan scrutiny sit in that rating alongside the margin structure. Adjacent: prescription dermatology therapeutics 2 13% 11.2x n=1 Niagen Bioscience Inc (NAGE) · Evommune, Inc. (EVMN) Claims, prescribers, clinical burden. On the 2 names in this group, Niagen Bioscience Inc (NAGE) is the one with a forward estimate, at 11.2x on 16% revenue growth; Evommune, Inc. (EVMN) carries no rating in the set. A regulated claim raises the cost of a launch and the value of substantiation already completed. Store-brand and private-label self-care 2 13% 9.5x Haleon plc (HLN) · Perrigo Company plc (PRGO) Supplying the price gap. Haleon plc (HLN) and Perrigo Company plc (PRGO) are carried at 9.5x between them. Commodity relief and retailer own-label mandates move this group's economics faster than brand advertising does. Adjacent models 2 13% 8.1x Bausch + Lomb Corporation (BLCO) · Prestige Consumer Healthcare Inc. (PBH) Bought on replenishment cadence. Bausch + Lomb Corporation (BLCO) and Prestige Consumer Healthcare Inc. (PBH) sit at 8.1x between them, BLCO on 6% revenue growth and PBH on a 33% margin. Habitual repurchase is the revenue quality a buyer underwrites in both.

  7. 07
    SECTION 03

    03

    This divider introduces the public-market valuation section ranking companies on forward earnings.

    From here, we rank the rated companies on EV/EBITDA for CY2027E and show how the set splits into two ratings. The following pages build the valuation case name by name.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS Ranked on Forward Earnings, the Set Splits into Two Ratings EV / EBITDA on CY2027E for the 12 companies with a forward estimate, out of 15 shown on the page. 03 of 06 Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    The Top of the Range Keeps Its Premium Even After Forecast Growth Is Credited

    This page ranks the twelve rated companies by EV/EBITDA and shows the sector median.

    Ranked on EV/EBITDA for CY2027E, the twelve rated companies split clearly: the top holds 14.2x even after crediting forecast growth, and the sector median sits at 9.8x. That the premium survives being priced against forward growth tells us the top of the range is not simply a growth story — it's also a quality-of-earnings story. The tier zones on this page are our own groupings, cut at the rated set's quartiles.

    Everything on this page

    03 · PUBLIC MARKET VALUATION The Top of the Range Keeps Its Premium Even After Forecast Growth Is Credited EV / EBITDA (CY2027E) · all 12 rated companies, sorted descending · sector median 9.8x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (12 of 15 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 14.2x CORE · median 9.8x DISCOUNT · median 4.0x Sector median 9.8x WHAT SEPARATES THE TWO ENDS The top holds 14.2x. The three names at the premium end are carried at 14.2x on CY2027E EV / EBITDA. A forward multiple already credits the growth sitting in the estimates, so a premium that survives it reads as a view on durability rather than on next year's momentum. The bottom sits at 4.0x. The three names at the discount end are carried at 4.0x. All three sell nutrition and meal-replacement products through distributor networks, where revenue quality is argued on retention rather than on retail facings. Six names hold the middle. Between the two ends sit 6 of the 12 companies with a forward estimate, including Haleon plc (HLN), Kimberly-Clark Corporation (KMB) and Prestige Consumer Healthcare Inc. (PBH). The middle band is where mix, channel breadth and retailer concentration are argued.

  9. 09
    03 · VALUATION DRIVERS

    The Faster-Growing Half Travels with a Modest Premium

    This page compares median EV/EBITDA between faster- and slower-growing cohorts, and between higher- and lower-margin cohorts.

    Splitting the rated set into faster- and slower-growing halves, and separately into higher- and lower-margin halves, shows the faster-growing half trading with only a modest premium. That's an association we observe in the data, not a causal claim. It tells us growth alone doesn't fully explain where a name sits in the range — margin and mix matter too.

    Everything on this page

    03 · VALUATION DRIVERS The Faster-Growing Half Travels with a Modest Premium Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=6; slower n=6; higher-margin n=6; lower-margin n=6). Driver readings are NeuraCap views on the supplied data — association, not causation. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/EBITDA, median per cohort · growth split at 4% · EBITDA-margin split at 16% Above the 4% Growth Line the Rating Is 10.3x; Below It, 8.9x Splitting the 12 companies with a forward estimate at 4% revenue growth puts 6 names above the line at 10.3x and 6 below at 8.9x. The gap is real but narrow, and it is an association rather than a mechanism — cohort composition and differences in estimate coverage could produce the same picture. Wide Margins Sit Across This Range, Not Only at Its Upper End Prestige Consumer Healthcare Inc. (PBH) reports a 33% margin and sits inside the middle band, while Waldencast plc (WALD) on a 7% margin sits at the upper end of the range. Profitability alone is not where the separation in this set shows up. Claims Substantiation Is an Asset a Buyer Can Actually Transfer Where a brand sells on a regulated claim, the clinical file, registrations and adverse-event obligations travel with the business, and diligence runs on net revenue realisation after trade deductions. Those assets sit alongside the ratings at the upper end of this range, and they are built years before anyone asks about them. The Private-Label Price Gap Sets the Test for a Pricing Record Two of the 15 companies here supply store brands and private label; most of the set sells branded against that gap. Where price/mix has held without volume forfeiture, the market has been paying inside the upper band; where promotion carried the revenue, the rating sits lower.

  10. 10
    03 · SITUATION MAP

    Where the Money Sits: Higher Ratings Pair with Faster Growth for 3 Names

    This page maps companies on EV/EBITDA against revenue growth, splitting each at the sector median.

    Cutting the set on EV/EBITDA against the sector median of 9.8x and on revenue growth against the covered median of 4%, we find three names where a higher rating pairs with faster growth. This is an observation about where the money currently sits, not a recommendation. It's a useful starting point for asking why those three names earned both a premium and growth at once.

    Everything on this page

    03 · SITUATION MAP Where the Money Sits: Higher Ratings Pair with Faster Growth for 3 Names Cut on EV / EBITDA vs the sector median (9.8x) (rows) and revenue growth vs the covered median (4%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Premium Rating, Faster Growth Above-median multiple · above-median revenue growth 3 names The Honest Company, Inc. (HNST) · Waldencast plc (WALD) · Niagen Bioscience Inc (NAGE) The Honest Company, Inc. (HNST), Waldencast plc (WALD) and Niagen Bioscience Inc (NAGE) sit above the 9.8x sector middle and above the covered growth line. The forward rating already credits the forecast, so the work here is holding gross margin while distribution and advertising build. Premium Rating, Slower Growth Above-median multiple · below-median revenue growth 3 names Colgate-Palmolive Company (CL) · Haleon plc (HLN) · Kimberly-Clark Corporation (KMB) Colgate-Palmolive Company (CL), Haleon plc (HLN) and Kimberly-Clark Corporation (KMB) hold an above-middle rating on low single-digit revenue growth. Price/mix, payout coverage and category leadership are what that rating is argued on, and a heavier promotional cycle is what tests it. Growth Without the Rating Below-median multiple · above-median revenue growth 3 names Bausch + Lomb Corporation (BLCO) · Prestige Consumer Healthcare Inc. (PBH) · Nature's Sunshine Products, Inc. (NATR) Bausch + Lomb Corporation (BLCO), Prestige Consumer Healthcare Inc. (PBH) and Nature's Sunshine Products, Inc. (NATR) are growing faster than the covered middle without a rating to match. Replenishment cadence, repeat purchase and retention are the evidence that would narrow that gap. Below on Both Lines Below-median multiple · below-median revenue growth 3 names Perrigo Company plc (PRGO) · Herbalife Nutrition Ltd. (HLF) · LifeVantage Corporation (LFVN) Perrigo Company plc (PRGO), Herbalife Nutrition Ltd. (HLF) and LifeVantage Corporation (LFVN) sit below the middle on both lines. Mix, SKU productivity and the cost of holding distribution are where the argument starts for these three.

  11. 11
    03 · GROWTH VS PROFITABILITY

    The Growth Half of the Grid Holds the Higher Ratings

    This page plots revenue growth against EBITDA margin and shows the median EV/EBITDA in each quadrant.

    Plotting revenue growth for CY2027E against EBITDA margin for CY2026E, cut at the covered medians of 4% growth and 16% margin, we see the growth half of the grid holding the higher median multiples. That pattern is directional, built on a small number of names in each quadrant. It tells us where the market is currently rewarding growth over margin, and where the reverse is true.

    Everything on this page

    03 · GROWTH VS PROFITABILITY The Growth Half of the Grid Holds the Higher Ratings Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2026E, y-axis) · 12 companies with both estimates · cuts at the covered medians (4% growth, 16% margin) · median EV/EBITDA per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/EBITDA (balanced n=2; margin-only n=4; growth-only n=4; neither n=2). Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 0% 5% 10% 15% 10% 20% 30% MARGIN ONLY median 10.9x BALANCED median 8.1x NEITHER median 5.3x GROWTH ONLY median 12.6x LFVN PRGO KMB HLF CL HLN HNST NATR BLCO WALD PBH NAGE x: revenue growth (CY2027E) · y: EBITDA margin (CY2026E) HOW TO READ THIS Read the grid on two lines: 4% revenue growth across, 16% margin up the side. The 4 names above the growth line and below the margin line are carried at 12.6x, and the 4 above the margin line and below the growth line at 10.9x. The 2 names clearing both bars, Bausch + Lomb Corporation (BLCO) and Prestige Consumer Healthcare Inc. (PBH), sit at 8.1x, and the 2 clearing neither at 5.3x — on 12 names, so treat the two-name cells as indicative. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 1 of 12 names clear it (PBH).

  12. 12
    03 · THE AGENDA

    Which Tier a Personal Care Business Trades in Is Associated with Four Decisions Owners Control

    This page frames four decisions owners face depending on which valuation tier their business sits in.

    We frame four decisions here — the ones an owner or acquirer should be resolving based on where their business sits in this range. These are observations built on the cohort data shown earlier, not recommendations. Working through them early is what lets a business get ahead of the rating it's likely to be argued on next.

    Everything on this page

    03 · THE AGENDA Which Tier a Personal Care Business Trades in Is Associated with Four Decisions Owners Control NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Decide Whether Price/mix or Volume Carries the Next Plan The names at the upper end of this set are argued on realised price and mix holding up, not on units. Settle internally which one the plan depends on, and what advertising level the answer requires, before the next category review fixes the facings. What changes the answer: Price realisation holding through a heavier promotional quarter without volume forfeiture. Test Whether the Brands Under One Roof Actually Share Plants and Advertising Portfolio coherence is a capital allocation question: which brands earn advertising support, which absorb plant capacity without earning facings, and which formats justify the changeover cost. The answer shapes where the cash goes next year. What changes the answer: A brand failing to hold ACV distribution while still consuming advertising and plant time. Prove Channel Travel Before the Rating Is Asked to Credit It Brands built in direct selling, professional or direct-to-consumer channels face the same question when they move to mass: does gross margin survive trade spend and does the claim survive the new label. The 3 nutrition and meal-replacement names in this set sit at the bottom tier while that question is open. What changes the answer: Sales per point of distribution rising in mass while gross margin after trade spend holds. Choose How Much Regulated Claim Burden the Portfolio Should Carry The monograph versus cosmetic claim boundary sets the clinical, labelling and adverse-event burden attached to each SKU. Carrying more of it costs money and buys a trust asset; carrying less keeps launches cheap and leaves the price gap easier for private label to close. What changes the answer: An ingredient restriction or reformulation cycle landing in a principal market.

  13. 13
    SECTION 04

    04

    This divider introduces the deal-evidence section, covering the recorded transactions and what each benchmarks.

    Next, we turn to recorded transactions: strategics have been paying mid-teens multiples, while a sponsor paid for cash earnings. Nine recorded transactions sit behind this section, and we use case studies to show what each was valued at and why.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Strategics Have Been Paying Mid-Teens; A Sponsor Paid for Cash Earnings What the 9 recorded transactions on this page were valued at, and what each one benchmarks. 04 of 06 Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

  14. 14
    04 · DEAL CASE STUDIES

    Mid-Teens for Brands with Claims and Distribution; Cash-Earnings Prices for Cost Structure

    This page walks through three of the twenty-five disclosed transactions as case studies on LTM multiples at announcement.

    Of twenty-five transactions with disclosed terms, we walk through three as case studies: a claims-led brand changing hands near 16.2x forward EBITDA, and a cost-led, cash-generative portfolio agreed near 7.8x. Both multiples are LTM at announcement and aren't directly comparable to the CY2027E public basis shown earlier — we're not claiming a spread between them. What the pairing tells us is that distribution and claims still command a premium at the deal table, while cost structure gets priced on cash earnings. The complete list of twenty-five transactions sits in the appendix.

    Everything on this page

    04 · DEAL CASE STUDIES Mid-Teens for Brands with Claims and Distribution; Cash-Earnings Prices for Cost Structure 3 of 25 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 53 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 21 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 May-2026 $2.7B Oaktree Capital Management L.P. Oaktree Capital Management L.P. takes Spectrum Brands Holdings, Inc. at a cash-earnings price. EV / LTM revenue 0.9x EV / LTM EBITDA 7.8x WHY THE DEAL HAPPENED A sponsor buying a multi-category consumables portfolio is buying cash earnings, plant absorption and a cost line it believes can be run tighter. The transaction suggests the underwriting sat on normalised EBITDA and cost structure rather than on the growth of any single brand. HOW THE TARGET WAS VALUED Recorded at $2.7B and 7.8x EBITDA. That sits below the middle of the traded range in this peer set, which is where portfolios argued on cost rather than on price realisation have been landing. Mar-2026 $1.4B Henkel US Operations Corp Henkel US Operations Corp buys Olaplex Holdings, Inc. and pays for the claim, not the shelf space. EV / LTM revenue 3.4x EV / LTM EBITDA 16.2x WHY THE DEAL HAPPENED Henkel US Operations Corp is a global brand owner with mass and professional distribution; Olaplex Holdings, Inc. is a claims-led hair brand built in the salon channel. The transaction suggests the buyer was paying for a formulation story and professional endorsement it could carry onto more shelves. HOW THE TARGET WAS VALUED Recorded at $1.4B and 3.4x revenue. A revenue multiple at that level only reads as sensible next to a gross margin structure wide enough to fund sustained advertising, which is the test buyers apply to emerging prestige brands. Jun-2025 $3.4B Suzano S.A. acquires International Family Care and Professional (IFP) Business EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED When a brand changes hands in this sector, the buyer is typically a strategic with shelf access and plants, or a sponsor assembling adjacent self-care brands. The fit question is the same either way: whether formulations, registrations, trademarks and co-manufacturer relationships transfer cleanly to the new owner. HOW THE TARGET WAS VALUED Pricing convention in this sector is a multiple of normalised, standalone EBITDA, struck after trade deductions, returns reserves and the advertising level a buyer believes is needed to hold share. Carve-out structures then carry an explicit dis-synergy schedule for plant absorption and sales coverage.

  15. 15
    SECTION 05

    05

    This divider introduces the strategic-implications section covering moves for owners, boards and acquirers.

    From the evidence so far, we turn to what it means for owners, boards and acquirers over the next twelve months. The following page sets out the moves that change where a business sits in this range.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS The Moves That Change Where a Business Sits in This Range What the evidence means for owners, boards and acquirers in this sector. 05 of 06 Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

  16. 16
    05 · STRATEGIC IMPLICATIONS

    The Same Range Points Owners, Boards and Acquirers Toward Different Moves

    This page sets out how owners, boards and acquirers should each read the same valuation range.

    We read the same range three ways: owners should protect price and mix through the next reset, boards should decide which brands keep earning advertising support, and acquirers should focus the negotiation on normalised EBITDA. These are our views drawn from the analysis in this report, framed as questions rather than recommendations. Working through them is what turns this valuation picture into a plan for the next twelve months.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS The Same Range Points Owners, Boards and Acquirers Toward Different Moves NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Revenue Quality Is the Line This Range Is Argued On Across the 12 companies with a forward estimate, the names at the upper end sell on claims, professional endorsement and habitual replenishment. The practical work is protecting price/mix through the next reset, holding gross margin after trade spend, and keeping advertising funded at the level share requires. FOR BOARDS Capital Allocation Decides Which Brands Keep Advertising Support Where a portfolio genuinely shares plants, sales coverage and advertising efficiency, comparable businesses in this set are carried in the upper band. Where a brand absorbs capacity without earning facings, that capital has a better use inside the same company. FOR ACQUIRERS Normalised EBITDA Is Where the Negotiation Actually Happens The transactions recorded here run on cash earnings struck after trade deductions, returns reserves and the advertising a buyer believes is needed to hold share. Work on net revenue realisation, retailer concentration and co-manufacturer dependency is what separates a mid-teens price from a cash-earnings price.

  17. 17
    SECTION 06

    06

    06.

    Section 06 of 06 — The Full Universe, Methodology and Sources. Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. Use this divider to reset the room before the section's pages; the progress dots show where the argument stands. 17

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

  18. 18
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier

    This page lists all rated public comparables on EV/EBITDA, grouped by valuation tier.

    This page carries all twelve rated companies on EV/EBITDA for CY2027E, shaded against the sector median of 9.8x, alongside three names without an eligible multiple. Every ticker links back to its underlying source, so any figure in the deck can be traced to its origin. This is the full company-level detail behind the segment and ranking pages shown earlier.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (9.8x); amber marks below · 12 rated companies; 3 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 12 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥12.2x · median 14.2x · 3 companies The Honest Company, Inc. HNST Mass-market personal care portfolios $515M 20.0x 4% 8% 12 Colgate-Palmolive Company CL Mass-market personal care portfolios $76.2B 14.2x 3% 24% 27 Waldencast plc WALD Mass-market personal care portfolios $362M 14.1x 11% 7% 20 CORE — 6.8x–12.2x · median 9.8x · 6 companies Haleon plc HLN Store-brand and private-label self-care $50.9B 11.6x 4% 27% 32 Niagen Bioscience Inc NAGE Adjacent: prescription dermatology therapeutics $173M 11.2x 16% 8% 26 Kimberly-Clark Corporation KMB Mass-market personal care portfolios $39.5B 10.3x 3% 22% 25 Bausch + Lomb Corporation BLCO Eye and lens care consumables $10.9B 9.3x 6% 19% 26 Perrigo Company plc PRGO Store-brand and private-label self-care $5.5B 7.4x 1% 18% 19 Prestige Consumer Healthcare Inc. PBH Consumer self-care and over-the-counter remedies $3.2B 6.9x 12% 33% 46 DISCOUNT — <6.8x · median 4.0x · 3 companies LifeVantage Corporation LFVN Adjacent: nutrition and meal-replacement products $76M 6.6x 0% 6% 6 Herbalife Nutrition Ltd. HLF Adjacent: nutrition and meal-replacement products $3.0B 4.0x 3% 13% 17 Nature's Sunshine Products, Inc. NATR Adjacent: nutrition and meal-replacement products $160M 2.9x 5% 10% 15

  19. 19
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This is the first of two pages listing all twenty-five precedent transactions with disclosed terms, newest first.

    This page lists precedent transactions with disclosed terms, newest first, out of twenty-five such transactions recorded in this tier. Multiples shown are LTM at announcement, and deal values link to the underlying filing. The remaining transactions continue on the next page.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 25 transactions with disclosed terms in this tier (46 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 53 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 21 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 25 transactions shown; the rest are in the companion workbook. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters May-2026 Oaktree Capital Management L.P. → Spectrum Brands Holdings, Inc. $2.7B 0.9x 7.8x Oaktree Capital Management L.P. announced Spectrum Brands Holdings, Inc. in May 2026 at $2.7B, recorded at 0.9x revenue. A revenue multiple below one on a multi-category consumables portfolio points at a price struck on earnings and cost absorption rather than on… Mar-2026 Henkel US Operations Corp → Olaplex Holdings, Inc. $1.4B 3.4x 16.2x Henkel US Operations Corp completed Olaplex Holdings, Inc. in March 2026 at 16.2x EBITDA. A professional-channel hair brand landing inside a global portfolio with mass and salon access is the clearest paid-up mark in this record. Nov-2025 n/a → The Clorox Company n/a n/a 12.3x The Clorox Company was recorded in November 2025 at 12.3x EBITDA. It is a reference for diversified portfolios where scale and retailer mandates carry the earnings. Nov-2025 n/a → The Procter & Gamble Company n/a n/a 14.0x The Procter & Gamble Company was recorded in November 2025 at 14.0x EBITDA. It marks where the largest diversified portfolios sit against the smaller brand platforms in this peer set. Nov-2025 n/a → Reckitt Benckiser Group PLC n/a n/a 12.6x Reckitt Benckiser Group PLC was recorded in November 2025 at 12.6x EBITDA. Health and hygiene portfolios with regulated claims cluster in this band rather than at the bottom of it. Nov-2025 n/a → Colgate-Palmolive Company n/a n/a 13.5x Colgate-Palmolive Company was recorded in November 2025 at 13.5x EBITDA. Dental and professional endorsement is part of what that band of pricing is argued on. Nov-2025 n/a → Haleon plc n/a n/a 13.6x Haleon plc was recorded in November 2025 at 13.6x EBITDA. The mark sits above where the same company trades in this peer set on forward earnings, which is worth holding in mind when benchmarking. Nov-2025 n/a → Church & Dwight Co., Inc. n/a n/a 15.5x Church & Dwight Co., Inc. was recorded in November 2025 at 15.5x EBITDA. Portfolios built on habitual replenishment and steady price realisation sit at the upper end of this record. Nov-2025 n/a → Colgate-Palmolive Company n/a n/a 13.5x A second recorded mark on Colgate-Palmolive Company from the same November 2025 window sits at the same level as the first. Repeat marks on one name tighten the benchmark rather than widen it.

  20. 20
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This is the second of two pages completing the list of twenty-five precedent transactions with disclosed terms.

    This page completes the list of precedent transactions with disclosed terms, shown newest first. As on the prior page, multiples are LTM at announcement and each deal value links to its underlying filing. Together, the two pages carry the full set of disclosed transactions behind the deal evidence shown earlier.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 25 transactions with disclosed terms in this tier (46 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 53 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 21 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 25 transactions shown; the rest are in the companion workbook. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Nov-2025 n/a → Reckitt Benckiser Group PLC n/a n/a 12.6x Value shown as recorded in the filing; status defaulted announced. Nov-2025 n/a → The Clorox Company n/a n/a 12.3x Value shown as recorded in the filing; status defaulted announced. Nov-2025 n/a → The Procter & Gamble Company n/a n/a 15.8x Value shown as recorded in the filing; status defaulted announced. Jul-2025 Church & Dwight Co., Inc. → Touchland n/a n/a 12.7x Jun-2025 Suzano S.A. → International Family Care and Professional (IFP) Business $3.4B n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Feb-2024 Compass Group Diversified Holdings LLC → The Honey Pot Company Holdings, LLC $380M n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Aug-2023 e.l.f. Beauty, Inc. → Naturium n/a n/a 21.0x Nov-2021 Waldencast Acquisition Corp. → Obagi Global Holdings Limited and Milk Makeup LLC n/a n/a 17.2x Apr-2021 Nestlé S.A. → The Bountiful Company (core brands) n/a n/a 16.8x

  21. 21
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    Sources, Assumptions and Data Quality.

    Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. 21

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Personal Care Products Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (12 of 15 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Personal Care Products and it clears the coverage gate with 12 of 15 companies (80%). EV / Revenue, P / E are carried as a cross-check. The set earns: 12 of the 12 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 17 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 763 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (762) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  22. 22

    In This Set, the Higher Ratings Sit with Proven Price/mix and Habitual Replenishment.

    This is the closing page stating that higher ratings in this set sit with proven price/mix and habitual replenishment.

    In this set, the higher ratings sit with proven price/mix and habitual replenishment. The companion tables alongside this deck carry the full universe and source index for any figure worth tracing further.

    Everything on this page

    In This Set, the Higher Ratings Sit with Proven Price/mix and Habitual Replenishment. NeuraCap AI — Personal Care Products Coverage September 2026 · Prepared by NeuraCap AI · Confidential Personal Care Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22

Sources and methodology

This report covers Personal Care Products (Consumer Staples › Household and Personal Products › Personal Care Products) with market data and consensus estimates as of September 28, 2026. The company universe is the 15 listed companies whose core business is Personal Care Products according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Bausch + Lomb Corporation (BLCO), Colgate-Palmolive Company (CL), Edgewell Personal Care Company (EPC), Evommune, Inc. (EVMN), Herbalife Nutrition Ltd. (HLF), Haleon plc (HLN), The Honest Company, Inc. (HNST), Kimberly-Clark Corporation (KMB), LifeVantage Corporation (LFVN), Niagen Bioscience Inc (NAGE), Nature's Sunshine Products, Inc. (NATR), Nu Skin Enterprises, Inc. (NUS), Prestige Consumer Healthcare Inc. (PBH), Perrigo Company plc (PRGO), Waldencast plc (WALD). The market map groups them by business vertical — Mass-market personal care portfolios: 6 companies (CL, KMB, EPC, HNST, WALD, NUS); Adjacent: nutrition and meal-replacement products: 3 companies (HLF, NATR, LFVN); Adjacent: prescription dermatology therapeutics: 2 companies (NAGE, EVMN); Store-brand and private-label self-care: 2 companies (HLN, PRGO); Adjacent models: 2 companies (BLCO, PBH). 12 of the 15 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Personal Care Products (Consumer Staples › Household and Personal Products › Personal Care Products) with market data and consensus estimates as of September 28, 2026. The company universe is the 15 listed companies whose core business is Personal Care Products according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Bausch + Lomb Corporation (BLCO), Colgate-Palmolive Company (CL), Edgewell Personal Care Company (EPC), Evommune, Inc. (EVMN), Herbalife Nutrition Ltd. (HLF), Haleon plc (HLN), The Honest Company, Inc. (HNST), Kimberly-Clark Corporation (KMB), LifeVantage Corporation (LFVN), Niagen Bioscience Inc (NAGE), Nature's Sunshine Products, Inc. (NATR), Nu Skin Enterprises, Inc. (NUS), Prestige Consumer Healthcare Inc. (PBH), Perrigo Company plc (PRGO), Waldencast plc (WALD). The market map groups them by business vertical — Mass-market personal care portfolios: 6 companies (CL, KMB, EPC, HNST, WALD, NUS); Adjacent: nutrition and meal-replacement products: 3 companies (HLF, NATR, LFVN); Adjacent: prescription dermatology therapeutics: 2 companies (NAGE, EVMN); Store-brand and private-label self-care: 2 companies (HLN, PRGO); Adjacent models: 2 companies (BLCO, PBH). 12 of the 15 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

17 records failed a validation gate and never feed a statistic in this report (15 excluded from aggregate; 2 quarantined). Each exclusion, with its reason: BLCO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · EPC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · EVMN — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · EVMN — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · EVMN — Implied EBITDA margin -3770.3% outside the plausible band [-100%, 80%] (effect: quarantined) · EVMN — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · EVMN — Implied EBITDA margin -51844.5% outside the plausible band [-100%, 80%] (effect: quarantined) · EVMN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · EVMN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · EVMN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · EVMN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HNST — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · PRGO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · WALD — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · WALD — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · WALD — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · WALD — Non-positive EPS; P/E is n/m (effect: excluded from aggregate)

Primary valuation basis and how it was chosen

Primary valuation basis: EV / EBITDA on CY2027E consensus (12 of 15 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Personal Care Products and it clears the coverage gate with 12 of 15 companies (80%). EV / Revenue, P / E are carried as a cross-check. The set earns: 12 of the 12 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 12 of 15 companies; EV / rEVenue: 15 of 15 companies; P/E: 12 of 15 companies. 2 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥12.2x, Core 6.8x–12.2x, Discount <6.8x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 9.8x = median(ev_ebitda CY2027E) (12 rated companies) · 14.2x = median(ev_ebitda CY2027E) within Premium tier (n=3) · 9.8x = median(ev_ebitda CY2027E) within Core tier (n=6) · 4.0x = median(ev_ebitda CY2027E) within Discount tier (n=3) · 10.3x = median(ev_ebitda CY2027E) | growth ≥ 4% (n=6) · 8.9x = median(ev_ebitda CY2027E) | growth < 4% (n=6) · 9.8x = median(ev_ebitda CY2027E) | EBITDA margin ≥ 16% (n=6) · 8.9x = median(ev_ebitda CY2027E) | EBITDA margin < 16% (n=6) · 22% = median Rule of 40 score (revenue growth + EBITDA margin) (n=12) · 8.1x = median(ev_ebitda CY2027E) within balanced quadrant (n=2) · 10.9x = median(ev_ebitda CY2027E) within marginOnly quadrant (n=4) · 12.6x = median(ev_ebitda CY2027E) within growthOnly quadrant (n=4) · 5.3x = median(ev_ebitda CY2027E) within neither quadrant (n=2)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Personal Care Products recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 46 transactions were recorded for this industry; 25 are shown. 21 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 18 × deal value unit unresolved; 22 × no evidence record; 8 × duplicate precedent id; 5 × divestiture roles reassigned. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 767 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Personal Care Products?

Company valuation reports run the same method against a single business — public or private.